Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dr. Nina Bhardwaj
With
Cancer Research Institute, New York City
In this study, we will examine whether DCs pulsed with candidate melanoma-specific peptides and KLH can boost CTL responses to melanoma antigens in melanoma patients who are clinically free of disease but at high risk for recurrence. This vaccine will be compared to direct injection of the same peptides with KLH and Montanide as adjuvant.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Resected stage IIB, IIC, or stage III melanoma.
Fully recovered from surgery
Human leukocyte antigen (HLA) A\*0201 positive.
Age \>18 years.
Karnofsky performance status: \>80% and normal labs.
You may not be if
Prior chemotherapy.
Known chronic infection with HIV, hepatitis B or C.
Patients with known autoimmune disease \[e.g. systemic lupus erythematosus (SLE), rheumatoid arthritis (RA)\]. Patients with vitiligo are not excluded.
Pregnant women.
Patients with known allergy to gentamicin, tobramycin, streptomycin and amikacin (risk of cross-reaction between aminoglycosides).
Patients who have known retinal or choroidal eye disease.
Allergy to shellfish.
Clareo Health | Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
